Change of MAX interactor 1 expression in an anti-thy1 nephritis model and its effect on mesangial cell proliferation

Cellular Physiology and Biochemistry

Volumn 27, Issue 3-4, 2011, Pages 391-400

  Liu, Xiaoluan ^a,b   Lv, Yang ^a   Xie, Yuansheng ^a   Hong, Quan ^a   Cai, Guangyan ^a   Zhang, Shujia ^a   Liu, Wen ^b   Chen, Xiangmei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Cell cycle; Cell cycle regulatory proteins; Cell proliferation; Mesangial cell; Mxi1

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; KI 67 ANTIGEN; MAX INTERACTOR 1; MYC PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MESANGIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

RATTUS;

EID: 79953804695     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000327966     Document Type: Article

References (23)

1. Xie Y, Chen X: Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol 2008;28:1-7. (Pubitemid 350126487)
2. Kawasaki Y: The pathogenesis and treatment of IgA nephropathy. Fukushima J Med Sci 2008;54:43-60.
3. Tsuji M, Monkawa T, Yoshino J, Asai M, Fukuda S, Kawachi H, Shimizu F, Hayashi M, Saruta T: Microarray analysis of a reversible model and an irreversible model of anti-Thy-1 nephritis. Kidney Int 2006;69:996-1004. (Pubitemid 43372174)
4. Cove-Smith A, Hendry BM: The Regulation of Mesangial Cell Proliferation. Nephron Exp Nephrol 2008;108:e74-e79. (Pubitemid 351704306)
5. Fukuda N, Tahira Y, Matsuda H, Matsumoto K: Transforming growth factor-beta as a treatment target in renal diseases. J Nephrol 2009;22:708-715.
6. Wang S, Wu H, Liu Y, Sun J, Zhao Z, Chen Q, Guo M, Ma D, Zhang Z: Expression of USP2-69 in mesangial cells in vivo and in vitro. Pathol Int 2010;60:184-192.
7. Tokunaga K, Uto H, Takami Y, Mera K, Nishida C, Yoshimine Y, Fukumoto M, Oku M, Sogabe A, Nosaki T, Moriuchi A, Oketani M, Ido A, Tsubouchi H: Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy. Biochem Biophys Res Commun 2010;399:144-149.
8. Wong WJ, Simon MC: The role of MXI1 in VHL deficient tumorigenesis. Cancer Biol Ther 2008;7:1628-1629.
9. Jefferson JA, Johnson RJ: Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 1999;12:297-307. (Pubitemid 30014640)
10. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
11. Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG, Wechsler DS: Mxi1, a Myc Antagonist, Suppresses Proliferation of DU145 Human Prostate Cells. Prostate 2001;47:194-204. (Pubitemid 32378371)
12. Hurlin PJ, Huang J: The MAX-interacting transcription factor network. Semin Cancer Biol 2006;16:265-274. (Pubitemid 44311036)
13. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW: Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:787-789.
14. Klisch TJ, Souopgui J, Juergens K, Rust B, Pieler T, Henningfeld KA: Mxi1 is essential for neurogenesis in Xenopus and acts by bridging the pan-neural and proneural genes. Dev Biol 2006;292:470-485.
15. Manni I, Tunici P, Cirenei N, Albarosa R, Colombo BM, Roz L, Sacchi A, Piaggio G, Finocchiaro G: Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression. Br J Cancer 2002;86:477-484. (Pubitemid 34185136)
16. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR: Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998;22:295-304. (Pubitemid 28304520)
17. Li XJ, Wang DY, Zhu Y, Guo RJ, Wang XD, Lubomir K, Mukai K, Sasaki H, Yoshida H, Oka T, Machinami R, Shinmura K, Tanaka M, Sugimura H: Mxi1 mutations in human neurofibrosarcomas. Jpn J Cancer Res 1999;90:740-746. (Pubitemid 29381103)
18. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T, Sage EH: SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004;91:915-925.
19. Fritz V, Fajas L: Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010;29:4369-4377.
20. Sadlier DM, Ouyang X, McMahon B, Mu W, Ohashi R, Rodgers K, Murray D, Nakagawa T, Godson C, Doran P, Brady HR, Johnson RJ: Microarray and bioinformatic detection of novel and established genes expressed in experimental anti-Thy1 nephritis. Kidney Int 2005;68:2542-2561. (Pubitemid 43251000)
21. Shibata T, Tamura M, Kabashima N, Serino R, Tokunaga M, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y: Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. Life Sci 2009;84:725-731.
22. Menssen A, Hermeking H: Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 2002;99:6274-6279.
23. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ: Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994;9:3635-3645. (Pubitemid 24359402)